BACKGROUND: The benefits of cardiac resynchronization in inducing reverse ventricular remodeling in patients with left ventricular (LV) systolic dysfunction have been well established. Still, up to 30% of the patients fail to derive significant improvement from this therapy. A subset of "nonresponders" experience deterioration in LV function following cardiac resynchronization therapy (CRT). Characteristics of this patient population, however, have not been studied. OBJECTIVE: To determine characteristics of patients who experience deterioration in LV function following CRT. METHODS: Clinical, electrocardiographic, and echocardiographic data were collected in 856 consecutive patients presenting for a new CRT device. For inclusion, all patients had an LV ejection fraction '40%, a QRS duration '120 ms, and available baseline and follow-up echocardiograms and electrocardiograms. Deterioration in LV function was defined as an absolute decrease of 5% or greater in ejection fraction from baseline. Multivariate models were constructed to identify variables significantly associated with deterioration. RESULTS: A total of 507 patients met inclusion criteria, of which 60 (11.8%) met criteria for deterioration. Patients with deterioration were more likely to be men (86.7% vs 66.9%; P = .002), have a non-left bundle branch block morphology (41.7% vs 23.7%; P = .001), and a history of atrial fibrillation (66.7% vs 51.7%; P = .03). On comparing the pre-CRT QRS duration with the first biventricular-paced QRS duration post-CRT implant, it was found that patients with LV deterioration had significant QRS widening than did those without deterioration (ms) (+3.9 ± 34.1 vs -9.0 ± 27.4, P = .007, respectively). In multivariate analysis, QRS widening indexed to the baseline QRS duration was significantly associated with LV deterioration (odds ratio 1.14 [1.06-1.23]; P = .001). CONCLUSION: QRS widening is associated with deterioration in LV function following CRT.
BACKGROUND: The benefits of cardiac resynchronization in inducing reverse ventricular remodeling in patients with left ventricular (LV) systolic dysfunction have been well established. Still, up to 30% of the patients fail to derive significant improvement from this therapy. A subset of "nonresponders" experience deterioration in LV function following cardiac resynchronization therapy (CRT). Characteristics of this patient population, however, have not been studied. OBJECTIVE: To determine characteristics of patients who experience deterioration in LV function following CRT. METHODS: Clinical, electrocardiographic, and echocardiographic data were collected in 856 consecutive patients presenting for a new CRT device. For inclusion, all patients had an LV ejection fraction '40%, a QRS duration '120 ms, and available baseline and follow-up echocardiograms and electrocardiograms. Deterioration in LV function was defined as an absolute decrease of 5% or greater in ejection fraction from baseline. Multivariate models were constructed to identify variables significantly associated with deterioration. RESULTS: A total of 507 patients met inclusion criteria, of which 60 (11.8%) met criteria for deterioration. Patients with deterioration were more likely to be men (86.7% vs 66.9%; P = .002), have a non-left bundle branch block morphology (41.7% vs 23.7%; P = .001), and a history of atrial fibrillation (66.7% vs 51.7%; P = .03). On comparing the pre-CRT QRS duration with the first biventricular-paced QRS duration post-CRT implant, it was found that patients with LV deterioration had significant QRS widening than did those without deterioration (ms) (+3.9 ± 34.1 vs -9.0 ± 27.4, P = .007, respectively). In multivariate analysis, QRS widening indexed to the baseline QRS duration was significantly associated with LV deterioration (odds ratio 1.14 [1.06-1.23]; P = .001). CONCLUSION: QRS widening is associated with deterioration in LV function following CRT.
Authors: Jan De Pooter; Milad El Haddad; Liesbeth Timmers; Frédéric Van Heuverswyn; Luc Jordaens; Mattias Duytschaever; Roland Stroobandt Journal: Ann Noninvasive Electrocardiol Date: 2015-09-22 Impact factor: 1.468
Authors: John G Cleland; William T Abraham; Cecilia Linde; Michael R Gold; James B Young; J Claude Daubert; Lou Sherfesee; George A Wells; Anthony S L Tang Journal: Eur Heart J Date: 2013-07-29 Impact factor: 29.983
Authors: Niraj Varma; David O'Donnell; Mohammed Bassiouny; Philippe Ritter; Carlo Pappone; Jan Mangual; Daniel Cantillon; Nima Badie; Bernard Thibault; Brian Wisnoskey Journal: J Am Heart Assoc Date: 2018-02-06 Impact factor: 5.501
Authors: Serge C Harb; Saleem Toro; Jennifer A Bullen; Nancy A Obuchowski; Bo Xu; Kevin M Trulock; Niraj Varma; John Rickard; Richard Grimm; Brian Griffin; Scott D Flamm; Deborah H Kwon Journal: Open Heart Date: 2019-07-05
Authors: Daniel Lapidot; Moshe Rav-Acha; Tali Bdolah-Abram; Rivka Farkash; Michael Glikson; Tal Hasin Journal: J Clin Med Date: 2022-02-26 Impact factor: 4.241